An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis

Reference

• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23_suppl_1):1–17.
   Google Scholar
• Trousseau A. Clinique médicale de l’hôtel Dieu de Paris. 2nd ed. Paris: JB Ballere et Fils; 1865.
   Google Scholar
• Sharma BK, Flick MJ, Palumbo JS. Cancer-associated thrombosis: a two-way street. Semin Thromb Hemost. 2019;45:559–568.
   PubMed Web of Science ®Google Scholar
• Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer‐associated venous thrombosis. Blood. 2013;122:1712‐23.
   PubMed Web of Science ®Google Scholar
• Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632‐476.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Ortel TL, Francis C. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27:4902–4911.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223–233.
   PubMed Web of Science ®Google Scholar
• Noble S, Pasi J. Epidemiology and pathphysiology of cancer-associated thrombosis. Br J Cancer. 2010;102 Suppl 1(Suppl 1):S2–S9.
   PubMedGoogle Scholar
• Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339‐46.
   Web of Science ®Google Scholar
• Sousou T, Khorana AA. New insights into cancer associated thrombosis. Arterioscler Thromb Vasc Biol. 2009;29:316–320.
   PubMed Web of Science ®Google Scholar
• Streiff MB. Association between cancer types, cancer treatments and venous thromboembolism in medical oncology patients. Clin Adv Hematol Oncol. 2013;11:349–357.
   PubMedGoogle Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377‐82.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Int Emergency Med. 2012;7:291–292.
   PubMed Web of Science ®Google Scholar
• Munoz Martin AJ, Ortega I, Font C, et al. Multivariable clinical‐genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118:1056‐61.
   PubMed Web of Science ®Google Scholar
• Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist. 2017;22:601‐8.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS‐cancer‐associated thrombosis study. Oncologist. 2017;22:1222‐31.
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102:1494–1501.
   PubMed Web of Science ®Google Scholar
• Al‐Samkari H, Song AB, Connors JM. Cancer‐associated thrombosis: where do we stand? Adv Cell Gene Ther. 2020;3:e73.
   Google Scholar
• Di Nisio M, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12. Art. No.: CD008500. DOI:10.1002/14651858.CD008500.pub4
   PubMedGoogle Scholar
• Lyman GH, Bohlke K, Falanga A, et al.; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442‐e444.
   Web of Science ®Google Scholar
• Agnelli G. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. NEJM. 2019;380:781–782.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou‐Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2018;380:711‐19.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–728.
   PubMed Web of Science ®Google Scholar
• Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2016;27(3):270–274.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484–490.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566—81.
   PubMed Web of Science ®Google Scholar
• Rafii H, Frère C, Benzidia I, et al. Management of cancer-related thrombosis in the era of direct oral anticoagulants: a comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). J Méd Vasc. 2020;45:28–40.
   PubMedGoogle Scholar
• Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988;208:227–240.
   PubMed Web of Science ®Google Scholar
• Guntupalli SR, Brennecke A, Behbakht H, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm. A randomized clinical trial. JAMA Network Open. 2020;3(6):e207410.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484‐88.
   Web of Science ®Google Scholar
• Monreal M, Falga C, Valdes M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4:1950‐56.
   Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low‐molecular‐weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146‐53.
   Web of Science ®Google Scholar
• Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–686.
   PubMed Web of Science ®Google Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venousthromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56‐70.
   Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189‐2204.
   Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–53.
   PubMed Web of Science ®Google Scholar
• Bavalia R, Middeldorp S, Weisser G, et al. Treatment of venous thromboembolism in special populations with direct oral anticoagulants. Thromb Haemost. 2020;120:899–911.
   PubMed Web of Science ®Google Scholar
• van der Hulle T, den Exter PL, Kooiman J, et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Duong A, Sing S, Taketa C, et al. Practical considerations for the use of direct oral anticoagulants in oncology patients. J Oncol Pharm Pract. 2020;26:692–702.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–624.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–2023.
   PubMed Web of Science ®Google Scholar
• McBane R II, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;1:411–421.
   Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599–1607.
   PubMed Web of Science ®Google Scholar
• Spehlmann ME, Frey N, Müller OJ. Prevention and treatment of venous thromboembolism in cancer patients. Herz. 2020;45:652–658. published online.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496–520.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543–603.
   PubMed Web of Science ®Google Scholar
• Mulder FI, van Es N, Kraaijpoel N, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res. 2020;185:13–19.
   PubMed Web of Science ®Google Scholar
• Carrier M, Blais N, Crowther M, et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol. 2018;25:329–337.
   PubMed Web of Science ®Google Scholar
• Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019;17:72–76.
   PubMed Web of Science ®Google Scholar
• Riess H, Prandoni P, Harder S, et al. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol. 2008;132:169–179.
   Google Scholar
• Xarelto (rivaroxaban) [ package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015.
   Google Scholar
• Peterson JJ, Hoehns JD. Administration of direct oral anticoagulants through enteral feeding tubes. J Pharm Technol. 2016;32:196–200.
   Web of Science ®Google Scholar
• Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). J Thromb Thrombolysis. 2017;43:343–351.
   PubMed Web of Science ®Google Scholar
• Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol. 2016;27:2825–2832.
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–1313.
   PubMed Web of Science ®Google Scholar
• Lee AYY. Anticoagulant therapy for venous thromboembolism in cancer. N Engl J Med. 2020;382:1650-1652.
   Google Scholar
• Cimminiello C, Anderson FA Jr. Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res. 2012;129:139–145.
   PubMed Web of Science ®Google Scholar
• Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120:1128–1136.
   PubMed Web of Science ®Google Scholar
• Hutchinson A, Rees S, Young A, et al. Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the Select-D trial. Palliat Med. 2019;33:510–517.
   PubMed Web of Science ®Google Scholar
• Noble S, Matzdorff A, Maraveyas A, et al. Assessing patients’ anticoagulation preferences for the treatment of cancer- associated thrombosis using conjoint methodology. Haematologica. 2015;100:1486–1492.
   PubMed Web of Science ®Google Scholar